IFS Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

IFS Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	-$3K	–	168
2020 Q4	$3K	Buy	+500	New	+$4.02K	﹤0.01%	143

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

IFS Advisors's SRNE Position: Q1 2021 in Review

IFS Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2021, closing a stake of 500 shares — an estimated $3K sold.

IFS Advisors first reported a position in SRNE in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 231 funds tracked by Wall St. Rank hold SRNE as of Q1 2021.

IFS Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
IFS Advisors sold 500 Sorrento Therapeutics, Inc. shares in Q1 2021, an estimated $3K.
IFS Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
IFS Advisors's Sorrento Therapeutics, Inc. position peaked at $3K in Q4 2020.
231 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2021.

Based on IFS Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.